| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| A661605-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $385.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Store at -80°C |
| Shipped In | Dry ice |
| Product Description | AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC 50 of 18 nM and a K d of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4 , TGFBR1 , and ALK7 . AZ12601011 inhibits mammary tumor growth. IC50& Target:ALK4 ALK7 In Vitro:AZ12601011 (0.01-10 μM; for 20 minutes) completely inhibits Phosphorylation of SMAD2. AZ12601011 (0.01 µM-10 µM) inhibits the activity of ALK4, ALK7 and TGFBR1. AZ12601011 inhibits 4T1 cells growth in vitro (IC 50 =0.4µM). MCE has not indep In Vivo:AZ12601011 (5mg/kg; oral gavage; twice daily; for 25 days) inhibits tumour growth and metastasis in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c mice at greater tha Biological Activity:AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC 50 of 18 nM and a K d of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4 , TGFBR1 , and ALK7 . AZ12601011 inhibits mammary tumor growth. |
Enter Lot Number to search for COA:
